More Good News for Affymax Shareholders
Affymax's share price jumped about 5% yesterday -- and it looks like deja vu for shareholders today. The stock was up once again and contributed to Affymax's year-to-date gain of more than 275%. The company's flagship product is the FDA-approved drug Omontys, which treats anemia in patients who are on dialysis and suffering from chronic kidney disease. Affymax is marketing the drug in collaboration with Takeda Pharmaceuticals, and their main competitor in this space is biotech giant Amgen and its drug Epogen. Amgen has a long-term agreement in place to sell Epogen to dialysis provider DaVita and has a non-exclusive contract with Fresenius Medical Care. Affymax, however, is trying to gain market share through deals with Fresenius Medical Care and other dialysis providers.
In this video, health care analysts Max Macaluso and David Williamson look at Affymax's recent rise and discuss the importance of Omontys' sales to the future of this stock.
Affymax is on a great run this week, but it wasn't selected as The Motley Fool's Top Stock for 2012. In this special report, our chief investment officer identifies his favorite company for the year. To read this report before the rest of the market catches on, click here -- it's absolutely free.
The article More Good News for Affymax Shareholders originally appeared on Fool.com.Max Macaluso , David Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.